Commit Biologics raised a $60 million seed round to advance COM002, a complement-powered immune engager, into IND-enabling work and into the clinic with first patient dosing expected in early 2028. Copenhagen-based Commit plans to also progress a second program toward IND. The company’s bispecific complement engager (BiCE) concept aims to deplete targeted pathogenic cell types using complement as the effector mechanism. Commit frames the approach as complement-directed cell removal rather than broad immune suppression, targeting cell populations implicated across oncology and autoimmune disease. The funding was led by Ackermans & van Haaren, with participation from AbbVie Ventures and M Ventures plus existing backers Bioqube Ventures, Korys and Novo Holdings. The capital and timelines raise near-term expectations for preclinical-to-IND execution on complement biology and safety.
Get the Daily Brief